| scholarly article | Q13442814 |
| P50 | author | Roberto D'Amico | Q28325060 |
| Michael Untch | Q38292680 | ||
| A Musolino | Q57076640 | ||
| P2093 | author name string | Laura Orlando | |
| Samanta Sarti | |||
| Antonio Frassoldati | |||
| Luigi Cavanna | |||
| Corrado Boni | |||
| Fabrizio Artioli | |||
| Valentina Guarneri | |||
| Patrizia Serra | |||
| Pierfranco Conte | |||
| Alberto Ravaioli | |||
| Federico Piacentini | |||
| Alberto Bottini | |||
| Luca Marini | |||
| Antonino Musolino | |||
| Giovanni Giardina | |||
| Giancarlo Bisagni | |||
| Katia Cagossi | |||
| Daniele Giulio Generali | |||
| Michela Bagnalasta | |||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| breast cancer | Q128581 | ||
| trastuzumab | Q412616 | ||
| P304 | page(s) | 1989-95 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study | |
| P478 | volume | 30 |
| Q95492561 | Q95492561 |
| Q38878220 | A Cytostatic Ruthenium(II)-Platinum(II) Bis(terpyridyl) Anticancer Complex That Blocks Entry into S Phase by Up-regulating p27(KIP1). |
| Q37143133 | A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer |
| Q101353577 | A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation |
| Q64066977 | A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study |
| Q59337418 | A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study |
| Q37534928 | A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer |
| Q35886083 | A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer |
| Q30758991 | Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial |
| Q38253136 | Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns. |
| Q38206546 | Advances in the approach to novel drug clinical development for breast cancer |
| Q50084900 | Advances in the management of HER2-positive early breast cancer |
| Q38159974 | Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades |
| Q27612411 | CIViC database |
| Q92713095 | Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy? |
| Q48212195 | Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis. |
| Q34694972 | Cardiac toxicity in breast cancer patients treated with dual HER2 blockade |
| Q36389339 | Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases |
| Q35742383 | Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer |
| Q64076568 | Comparative Efficacy and Tolerability of Neoadjuvant Immunotherapy Regimens for Patients with HER2-Positive Breast Cancer: A Network Meta-Analysis |
| Q38111772 | Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues |
| Q37135365 | Current approaches for neoadjuvant chemotherapy in breast cancer |
| Q27011658 | Current treatment of early breast cancer: adjuvant and neoadjuvant therapy |
| Q91693727 | De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study |
| Q38586993 | Designs of preoperative biomarkers trials in oncology: a systematic review of the literature. |
| Q36281513 | Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials |
| Q38220338 | Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis |
| Q91637188 | Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q26785612 | Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer |
| Q30941327 | Dual HER2 blockade: preclinical and clinical data |
| Q54405256 | Dual HER2 targeting for early breast cancer. |
| Q34009045 | Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer |
| Q87599247 | Dual targeting of HER2 with lapatinib and trastuzumab |
| Q33829405 | ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression |
| Q34169075 | Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review |
| Q37577947 | Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2-positive breast cancer: a meta-analysis of randomized controlled trials |
| Q36250585 | Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence |
| Q37704313 | Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials |
| Q54338904 | Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice. |
| Q47377842 | Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy |
| Q57129922 | Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a r |
| Q61987563 | Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer |
| Q37301435 | HER story: the next chapter in HER-2-directed therapy for advanced breast cancer |
| Q47965547 | HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma. |
| Q35551522 | HER2-directed therapy: current treatment options for HER2-positive breast cancer |
| Q42506198 | HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. |
| Q38301236 | HER2-family signalling mechanisms, clinical implications and targeting in breast cancer |
| Q37185872 | HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment |
| Q39034850 | HER2-positive breast cancer |
| Q51663342 | Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. |
| Q41149668 | Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies. |
| Q42497114 | Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial |
| Q37228051 | International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). |
| Q45855244 | Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials |
| Q36440625 | Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy |
| Q35794915 | Landscape of neoadjuvant therapy for breast cancer |
| Q46764831 | Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial |
| Q35042071 | Lapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis of randomized controlled trials |
| Q36962531 | Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells |
| Q42677733 | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response |
| Q34372166 | Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence |
| Q44048395 | Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer |
| Q38350939 | Management of locally advanced breast cancer-perspectives and future directions |
| Q37166436 | Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. |
| Q36440214 | Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer |
| Q34120668 | Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer |
| Q37123227 | Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer |
| Q37384929 | Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial |
| Q92484201 | Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study |
| Q36914142 | Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer |
| Q47782850 | Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). |
| Q37145188 | Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future |
| Q37022428 | Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer |
| Q54491035 | Neoadjuvant chemotherapy in breast cancer-insights from the German experience. |
| Q55428234 | Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations. |
| Q86732550 | Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel |
| Q35345642 | Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials |
| Q37128756 | Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer |
| Q27694514 | Neoadjuvant therapy in the treatment of breast cancer |
| Q27001729 | Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications |
| Q46419524 | Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial |
| Q54481763 | Neoadjuvant treatment for HER-2-positive and triple-negative breast cancers. |
| Q35005762 | Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study |
| Q38180007 | New HER2-positive targeting agents in clinical practice |
| Q38782016 | New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer |
| Q57106864 | Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs |
| Q37491455 | Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients |
| Q57020377 | Optimal treatment of early stage HER2-positive breast cancer |
| Q57111046 | Optimizing (neo)adjuvant treatment of HER2-positive breast cancer |
| Q39767744 | PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. |
| Q36181642 | PRP4K is a HER2-regulated modifier of taxane sensitivity |
| Q102141449 | Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07) |
| Q92717756 | Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination |
| Q44134898 | Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial |
| Q28291395 | Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) |
| Q49668714 | Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety stu |
| Q35947019 | Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomogr |
| Q48102534 | Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host. |
| Q36853593 | Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy |
| Q38786102 | Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge |
| Q34655579 | Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q61454343 | Primary medical therapy and breast conservation treatment: the medical oncology perspective |
| Q60930844 | Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution |
| Q36064908 | Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer |
| Q38387030 | RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. |
| Q92713306 | Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer |
| Q39024002 | Receptor tyrosine kinases in carcinogenesis |
| Q38420000 | Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size |
| Q28072897 | Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies |
| Q33433275 | Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer. |
| Q89543772 | Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy |
| Q44692841 | Risk of selected gastrointestinal toxicities in breast cancer patients treated with regimens containing lapatinib; a pooled analysis of randomized controlled studies |
| Q35077315 | Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis |
| Q38985441 | Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer. |
| Q60913102 | Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial |
| Q38231605 | Semi-xenotransplantation: the regenerative medicine-based approach to immunosuppression-free transplantation and to meet the organ demand. |
| Q91705320 | Smart Targeting To Improve Cancer Therapeutics |
| Q38409756 | Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy |
| Q38212607 | Surgical treatment of primary breast cancer in the neoadjuvant setting |
| Q38980703 | Targeted adjuvant therapy in breast cancer |
| Q34042715 | Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years? |
| Q60921913 | Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis |
| Q89558676 | The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer |
| Q35812158 | The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer |
| Q36064912 | The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer |
| Q36967905 | The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis |
| Q38683638 | The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations? |
| Q30251738 | Translating neoadjuvant therapy into survival benefits: one size does not fit all. |
| Q38052616 | Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients |
| Q38974785 | Trastuzumab cardiotoxicity: from clinical trials to experimental studies |
| Q37632118 | Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. |
| Q24194019 | Trastuzumab-containing regimens for metastatic breast cancer |
| Q35740877 | Treatment of HER2-positive breast cancer. |
| Q28081124 | Treatment of early-stage HER2+ breast cancer-an evolving field |
| Q36021424 | Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. |
| Q38123762 | Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer |
| Q38100711 | Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer |
| Q51304741 | Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis. |
| Q36871664 | Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule |
Search more.